QPS Netherlands BV, Groningen, The Netherlands.
Eur J Clin Pharmacol. 2013 May;69(5):1083-90. doi: 10.1007/s00228-012-1443-y. Epub 2012 Nov 10.
BACKGROUND/AIM: Timed interval cerebrospinal fluid (CSF) sampling by indwelling catheterization can be a valuable corroborative tool for the pharmacokinetic and pharmacodynamic assessment of drugs. CSF sampling in studies on drug candidates for Alzheimer's disease have been conducted in evaluations of the biomarkers acetylcholine (ACh), tau proteins, amyloid precursor protein and beta-amyloid fragments. The primary aim of this study was to study the feasibility and the burden on the healthy volunteers of serial CSF sampling within the contract research organization environment in order to establish a standardized research tool for future drug development studies.
This study is a validation study in healthy subjects: eight healthy male subjects aged 55-75 years were enrolled. After eligibility had been confirmed, the subjects were admitted to the clinical pharmacology unit 2 days before starting the CSF sampling procedure. Hydration by drip infusion of 2 L saline was performed for 24 h before starting the CSF sampling procedure, and for antithrombotic purposes, Fraxiparine (nadroparine calcium) was given 12 and 36 h after intradural catheterization. CSF catheterization was performed by board-certified anesthesiologists with experience in inserting indwelling intrathecal catheters. Subjects only required to remain in a horizontal position for the first 24 h after removal of the catheter. CSF and blood samples were collected by interval sampling over a 30-h period.
The study was completed by seven of the eight subjects. Six subjects who completed the study reported adverse effects (AEs) which were all mild and from which they recovered during their stay in the clinic. A total of 25 AEs were reported of which 13 were considered to be procedure-related. The procedure was well tolerated by all participating subjects, and the VAS scale scores for headache and back pain were low. CSF samples were analyzed for ACh. All values were above the lowest limit of quantification. On average, the ACh concentration started at a low level but rose between 1 and 2 h after insertion of the catheter and then remained high during the whole sampling period up to 30 h.
Serial sampling of CSF in seven healthy volunteers up to 30 h occurred without serious complications and was well tolerated. The CSF collected was of good quality and facilitated the assessment of an Alzheimer's disease-sensitive biomarker. We conclude that this validation study can form the basis for future patient studies aimed at elucidating disease mechanisms and the pharmacodynamics of drugs in the developmental stage.
背景/目的:留置导管法进行时间间隔的脑脊液(CSF)采样可以成为药物药代动力学和药效学评估的有价值的佐证工具。在阿尔茨海默病候选药物的研究中,已经进行了 CSF 采样以评估乙酰胆碱(ACh)、tau 蛋白、淀粉样前体蛋白和β-淀粉样片段等生物标志物。本研究的主要目的是研究在合同研究组织环境中对健康志愿者进行连续 CSF 采样的可行性和负担,以便为未来的药物开发研究建立标准化的研究工具。
这是一项在健康受试者中的验证研究:共纳入 8 名年龄在 55-75 岁的健康男性受试者。在确认合格后,受试者在开始 CSF 采样程序前 2 天入住临床药理学病房。在开始 CSF 采样程序前 24 小时通过静脉滴注 2L 生理盐水进行补液,并在硬膜内置管后 12 和 36 小时给予 Fraxiparine(那屈肝素钙)进行抗血栓治疗。CSF 导管插入由具有插入留置鞘内导管经验的认证麻醉师进行。受试者仅需在移除导管后的头 24 小时内保持水平位置。通过 30 小时的间隔采样采集 CSF 和血液样本。
8 名受试者中有 7 名完成了该研究。完成研究的 6 名受试者报告了不良反应(AE),均为轻度,且在诊所住院期间已恢复。共报告了 25 例 AE,其中 13 例被认为与操作过程相关。所有参与的受试者均能很好地耐受该操作,且头痛和背痛的 VAS 评分较低。CSF 样本被分析了 ACh。所有值均高于最低定量下限。平均而言,ACh 浓度开始较低,但在导管插入后 1-2 小时开始升高,然后在整个采样期间保持较高水平,直至 30 小时。
7 名健康志愿者连续 30 小时 CSF 采样未发生严重并发症,且耐受性良好。采集的 CSF 质量良好,有助于评估阿尔茨海默病敏感生物标志物。我们得出结论,这项验证研究可以为未来的患者研究奠定基础,旨在阐明疾病机制和药物在开发阶段的药效学。